A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis.

Anita D SouzaAniko SzaboIdayat AkinolaMuriel FinkelKathryn E Flynn

Published in: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2023)

Significant and persistent symptom burden is seen in AL amyloidosis. Patient-reported outcomes should be routinely measured and used to provide best supportive care to all AL amyloidosis patients, including long-term survivors and those not on active therapy.

Keyphrases

patient reported outcomes
multiple myeloma
healthcare
risk factors
palliative care
end stage renal disease
physical activity
chronic kidney disease
stem cells
newly diagnosed
pain management
prognostic factors
mesenchymal stem cells
cell therapy